Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Cancer Surgery
Eye cancer treatment
What eye cancer treatment involves, including plaque brachytherapy, proton beam therapy, vitrectomy and surgical enucleation. We examine survival rates and vision preservation, comparative costs in Turkey, the UK, the US and Germany, what to expect before and after therapy, practical recovery timelines, potential complications, and key questions to ask your ocular oncology multidisciplinary team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Cancer Surgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Eye Cancer Treatment
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Eye cancer treatment in Turkey: what it is and how it works
Eye cancer treatment encompasses specialized therapies designed to eradicate intraocular tumours—most commonly uveal melanoma, ocular lymphoma, and retinoblastoma—while preserving as much ocular structure and functional vision as clinically possible. In modern ocular oncology, the standard of care has transitioned significantly from immediate eye removal (enucleation) to advanced eye-sparing interventions. These include radioactive plaque brachytherapy using Ruthenium-106 or Iodine-125 isotopes, stereotactic radiotherapy, transpupillary thermotherapy, and microsurgical local resection. When an intraocular tumour is too advanced for eye-preserving techniques, enucleation combined with custom orbital implant reconstruction provides definitive tumour clearance. Specialized centres in Turkey offer comprehensive ophthalmic oncology evaluations, advanced radiotherapeutic platforms, and reconstructive ocular surgery.
Managing ocular malignancies requires exact diagnostic staging, including high-frequency ultrasound biomicroscopy, fundus fluorescein angiography, optical coherence tomography, and systemic liver imaging to detect any distant disease. This clinical guide explains how modern ocular therapies work, what published clinical trials say about tumour control and vision preservation, comparative costs across Turkey, the UK, the US, and Germany, and what recovery involves. To explore how eye therapies fit within wider cancer services, you can review our guide to oncology treatments in Turkey.
How does ocular plaque brachytherapy and targeted radiation work?
The principal eye-sparing technique for medium-sized choroidal melanomas is radioactive episcleral plaque brachytherapy. The mechanism relies on delivering a concentrated, therapeutic dose of ionising radiation directly through the sclera into the tumour base while minimising radiation exposure to adjacent delicate tissues such as the fovea and optic nerve. A custom-shaped gold or acrylic plaque containing radioactive seeds (most commonly Iodine-125 in North America and Ruthenium-106 in Europe and Turkey) is temporarily affixed to the outside of the eyeball directly beneath the tumour.
The plaque remains in place for three to seven days, during which radiation damages the DNA of the malignant tumour cells, halting their replication and causing progressive tumour regression over many months. For tumours situated dangerously close to the optic disc, or where plaque placement is mechanically challenging, proton beam radiotherapy or stereotactic fractionated photon radiotherapy delivers sub-millimetre focused external radiation beams. Alternatively, for tiny choroidal tumours, infrared laser diode transpupillary thermotherapy heats the tumour tissue to induce coagulative necrosis.
Does eye cancer treatment work and what does the evidence show?
Yes, modern eye cancer treatment achieves high rates of local tumour control when administered by trained ocular oncologists. The landmark Collaborative Ocular Melanoma Study, supported by the National Eye Institute, evaluated thousands of patients over multi-year follow-ups and demonstrated that plaque brachytherapy provides equivalent overall survival rates compared to total surgical enucleation for medium-sized choroidal melanomas. Long-term clinical registries indicate that local tumour control with episcleral brachytherapy exceeds 90 to 95 per cent.
However, patients must understand what the evidence does and does not support. While local eye-conserving therapy reliably halts tumour growth within the eye, it does not alter systemic metastatic risk, which is predominantly determined by the tumour's genetic profile, such as monosomy 3 and BAP1 gene mutations. Furthermore, eye-preserving radiotherapy does not guarantee normal eyesight. Radiation retinopathy, macular oedema, and radiation-induced cataracts can cause progressive vision loss over the years following treatment. Honest clinical teams clearly distinguish between tumour eradication and visual acuity preservation, providing realistic expectations based on the tumour's initial dimensions and proximity to the macula.
Eye cancer treatment cost in Turkey compared with the UK, US and Germany
Eye cancer treatment cost varies significantly based on the chosen modality, tumour complexity, whether radioactive plaque isotopes must be custom-ordered, hospital stay duration, and aftercare requirements. In private medical centres in the UK and the United States, specialized ocular radiation or enucleation can carry substantial out-of-pocket expenses, whereas hospitals in Turkey provide treatment packages at lower operating overheads. The table below outlines approximate price ranges for comprehensive ocular cancer care across major destinations.
| Country | Approximate cost range |
|---|---|
| Turkey | €5,000 – €14,000 |
| United Kingdom | €12,000 – €28,000 |
| United States | €25,000 – €55,000 |
| Germany | €11,000 – €26,000 |
Several variables influence the final eye cancer treatment price. Plaque brachytherapy requires specialised nuclear medicine coordination, custom radiation dosimetry planning, two surgical sessions for plaque placement and removal, and an inpatient stay in a radiation-shielded room. In contrast, enucleation requires a single operation followed by orbital integration and outpatient prosthetic eye fitting. Standard international packages in Turkey generally include pre-operative imaging with B-scan ultrasound, surgical fees, anaesthesia, the custom radioactive plaque or external radiation cycles, hospital accommodation, post-operative medications, and local airport transfers. You can request a personalized, written price breakdown through our free quote portal.
Plaque brachytherapy, stereotactic radiotherapy or enucleation?
Selecting the right intervention depends on tumour thickness, basal diameter, anatomical location within the uveal tract, and whether the tumour has caused extensive retinal detachment. Just as solid tumour oncology balances organ-preserving surgeries like a lumpectomy against total resection, ocular oncology weighs globe-preserving brachytherapy against enucleation. In advanced, non-salvageable cases where tumour clearance requires complete organ removal, analogous to radical oncological resections like the removal of colon cancer, enucleation ensures complete tumour eradication.
| Method | Best suited to | Typical limits |
|---|---|---|
| Plaque brachytherapy | Small to medium choroidal tumours up to 10 mm height | Requires two surgeries; risk of late radiation retinopathy |
| Stereotactic radiotherapy | Tumours adjacent to the optic disc or ciliary body | Requires rigid head immobilisation and multiple fractions |
| Enucleation | Large tumours (>10 mm height), painful blind eyes, extraocular extension | Complete loss of the biological eye; requires an ocular prosthesis |
No single approach suits every ocular oncology patient. Small peripheral tumours respond well to plaque brachytherapy or thermotherapy, whereas tumours encircling the optic nerve often necessitate particle radiation or enucleation to avoid severe complications. A multidisciplinary tumour board must review your diagnostic imaging before confirming which technique offers the safest oncological outcome.
Who is an appropriate candidate for eye-sparing cancer therapy?
Appropriate candidates for eye-sparing radiotherapy are adult or paediatric patients diagnosed with localized intraocular tumours that do not exceed standard safety dimensions, generally less than 10 mm in apical height and less than 16 to 18 mm in largest basal diameter. Candidates must have sufficient scleral integrity to support plaque placement and manageable retinal detachment. In addition, candidates must be medically stable to undergo general or regional peribulbar anaesthesia for surgical placement.
Patients who are not suitable for eye-conserving radiotherapy include those with extensive extraocular tumour extension into the orbit, tumours filling more than half of the globe, diffuse ring melanoma of the ciliary body, or blind, painful eyes resulting from neovascular glaucoma. In these clinical situations, enucleation is the safer medical choice to eliminate intractable pain and prevent further local spread. Severe systemic comorbidities that prevent safe travel or anaesthesia also require local stabilization before considering overseas treatment.
Step-by-step: what happens during plaque radiotherapy and surgery?
For patients undergoing radioactive plaque brachytherapy, treatment proceeds through a structured clinical pathway. First, comprehensive baseline examinations take place, including calibrated A-scan and B-scan ultrasonography and computerised three-dimensional treatment planning to calculate the exact radiation dwell time needed for tumour sterilisation. The initial operation is performed under general anaesthesia or deep local anaesthesia with monitored sedation. The ophthalmic surgeon exposes the sclera, precisely locates the tumour margins using intraoperative transillumination or indirect ophthalmoscopy, and sutures the radioactive plaque to the scleral wall directly over the tumour base.
The patient then recovers in a specialized hospital room with appropriate radiation safety precautions. Over the next three to seven days, continuous low-dose radiation is delivered to the tumour apex. Once the target radiation dose, typically 70 to 85 Gray to the tumour apex, has been completed, a second, brief surgical procedure is performed under local or general anaesthesia to remove the plaque and close the conjunctiva. If enucleation is performed instead, the eye is surgically removed, a porous polyethylene or hydroxyapatite orbital implant is inserted to restore socket volume and preserve muscle movement, and a temporary conformer shield is positioned.
Eye cancer treatment recovery, travel timeline and aftercare
Planning your travel and recovery timeline is essential when undertaking eye cancer treatment abroad. For plaque brachytherapy, international patients typically stay in Turkey for 8 to 12 days. This duration covers pre-operative tumour mapping, the 3 to 7 days of plaque wear, plaque removal surgery, and post-operative evaluations before clearing the patient for air travel. Following surgery, mild periocular swelling, lid bruising, and temporary double vision are common.
During early eye cancer treatment recovery, patients wear a protective eye shield, apply prescribed antibiotic and anti-inflammatory eye drops, and avoid heavy lifting, straining, or submerging the eye in water for four to six weeks. For patients undergoing enucleation, recovery involves wearing an acrylic conformer for four to eight weeks until the socket heals, after which an ocularist hand-crafts and fits a custom prosthetic eye matching the patient's natural iris and sclera. Routine follow-up visits with dilated fundus examinations and hepatic ultrasounds are scheduled at 3, 6, and 12 months to monitor tumour regression and general health.
Eye cancer treatment before and after: what are realistic expectations?
Understanding what occurs before and after eye cancer treatment helps patients establish practical expectations. Before treatment, patients often present with visual distortions, flashes of light, floaters, visual field deficits, or no symptoms at all when tumours are discovered during routine eye checks. After radiation therapy, tumours do not vanish immediately; instead, ultrasound imaging documents gradual shrinkage, flattening, and internal calcification over 12 to 24 months, eventually leaving a stable, flat pigmented scar.
Patients should not expect before-and-after photographic comparisons to demonstrate dramatic cosmetic changes, because intraocular treatments occur entirely inside the globe. The appearance of the external eye remains largely unchanged, although mild conjunctival redness or a minor drooping of the upper eyelid can occasionally persist. For enucleation patients, modern prosthetic eye fabrication provides remarkable aesthetic symmetry and natural socket movement, allowing patients to maintain their customary facial appearance. However, visual outcomes depend on tumour location: tumours situated near the macula or optic nerve carry a substantial likelihood of reduced central acuity over time due to radiation effects.
Risks, side effects and vision changes after eye cancer therapy
All oncological eye interventions carry distinct clinical risks. According to the Royal College of Ophthalmologists and the American Academy of Ophthalmology, late complications following radiation brachytherapy relate primarily to collateral radiation damage to vascular and neural structures. The most frequent secondary complication is radiation retinopathy—characterised by microaneurysms, retinal haemorrhages, and macular oedema—which can manifest one to three years after treatment. Other acknowledged risks include radiation-induced cataracts, neovascular glaucoma, dry eye syndrome, vitreous haemorrhage, and optic neuropathy.
For enucleation, potential complications include orbital implant exposure, extrusion, socket contracture, infection, or chronic discharge, although serious complications occur in fewer than 5 per cent of cases in specialized surgical units. If radiation complications develop, interventions such as intravitreal anti-VEGF injections, laser photocoagulation, or cataract extraction help manage side effects and stabilise visual function. Transparent clinics provide detailed informed consent discussing both tumour control probabilities and long-term vision risks.
How to choose an ocular oncology centre and questions to ask
Eye cancer treatment requires highly specialized expertise combining ophthalmic surgery, radiation physics, and medical oncology. When evaluating international clinics, ensure the hospital features a dedicated ocular oncology service led by fellowship-trained ophthalmic surgeons who collaborate with accredited radiation oncologists. The facility must have access to high-resolution ophthalmic ultrasound, certified radioactive plaque isotopes, and advanced orbital reconstruction capabilities. Red flags include facilities without multidisciplinary tumour boards, surgeons who lack specific ocular oncology credentials, pressure to make immediate non-refundable payments, or irresponsible guarantees of complete vision preservation.
To understand the organizational pathway, review how it works on our platform. Before committing to treatment, consider asking the clinical team the following questions:
- What is the precise histological or clinical classification, basal diameter, and apical height of my tumour?
- Which treatment modality—plaque brachytherapy, stereotactic radiation, or enucleation—offers the best balance of tumour control and safety for my case?
- What radioactive isotope do you plan to use, and how many days will the plaque remain in place?
- What are the realistic visual acuity expectations for my eye following radiation or surgery?
- What emergency protocols and shielding procedures are in place during my inpatient stay?
- How will my post-treatment follow-up and monitoring for radiation retinopathy or metastatic screening be coordinated with my local doctors?
You can submit your existing ophthalmic scans and medical records for expert assessment by requesting a free quote today.
Hospitals with Oncology in Turkey
Frequently asked questions
Eye cancer treatment comprises specialized therapies to eliminate tumours inside the eye, such as uveal melanoma and retinoblastoma. Depending on tumour size and location, treatments include radioactive plaque brachytherapy, stereotactic radiation, laser thermotherapy, or surgical removal of the eye (enucleation) with custom prosthetic reconstruction to restore natural facial appearance.
Yes, international clinical trials, including the Collaborative Ocular Melanoma Study, demonstrate that plaque brachytherapy achieves local tumour control rates exceeding 90 to 95 per cent for medium-sized choroidal melanomas. While treatment successfully halts intraocular tumour growth, ongoing surveillance is necessary because systemic metastatic risk depends primarily on tumour cellular genetics.
Approximate costs for eye cancer treatment in Turkey typically range from €5,000 to €14,000, compared with €12,000 to €28,000 in the UK and up to €55,000 in the US. The price depends on whether radioactive plaque isotopes, stereotactic radiation, or enucleation with an orbital implant is required.
Before treatment, patients undergo detailed ocular ultrasound and optical coherence tomography. Afterwards, treated tumours shrink slowly over one to two years, leaving a stable scar. Vision may change gradually if radiation affects the macula. For enucleation patients, a custom ocular prosthesis restores natural symmetry and cosmetic appearance.
Initial surgical recovery takes two to four weeks, during which swelling subsides and eye drops prevent infection. Plaque brachytherapy patients resume routine daily activities within a month, whereas enucleation patients receive their final custom prosthetic eye four to eight weeks post-surgery once the orbital socket has fully healed.
Surgeries are performed under general or local peribulbar anaesthesia, ensuring no discomfort during the procedure. Afterwards, patients typically experience mild to moderate aching, eyelid tightness, and light sensitivity for several days. These post-operative symptoms are effectively managed with prescribed oral pain relievers and soothing eye drops.
Local tumour eradication following plaque brachytherapy or surgical enucleation is intended to be permanent. Long-term surveillance with dilated eye examinations and liver imaging is maintained indefinitely, as delayed radiation effects can emerge years later and distant metastases require prompt detection by oncologists.
Eye cancer treatment is safe and highly standardised when carried out in accredited oncology hospitals by specialized ophthalmic surgeons. Potential long-term side effects include radiation retinopathy, cataracts, and dry eyes, which multidisciplinary teams actively monitor and manage with preventative therapies such as anti-VEGF injections.
Neither treatment is universally preferable. Plaque brachytherapy preserves the biological eye and often maintains partial vision for small-to-medium tumours. Enucleation is reserved for very large tumours, painful blind eyes, or extensive extraocular growth where preserving the globe poses unacceptable health risks or persistent discomfort.
Most international patients stay in Turkey for 8 to 12 days for plaque brachytherapy. This allows time for pre-operative imaging, plaque positioning, three to seven days of targeted radioactive plaque delivery, plaque removal, and final ophthalmic checks before returning home safely.
Patient stories